Oncology Drugs - Mauritius

Mauritius

The market for Oncology Drugs market in Mauritius is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$15.24m in 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 14.97% from 2024 to 2028.
As a result, the market volume is expected to reach US$26.63m by 2028.
When comparing in Mauritius to other countries on a global scale, it is worth noting that United States will generate the highest revenue in the Oncology Drugs market.
In 2024, United States is projected to generate a staggering US$114,600.00m in revenue.
Mauritius is experiencing a surge in demand for innovative oncology drugs, driven by a growing population and increasing awareness of the importance of cancer treatment.

Key regions: Germany, India, United Kingdom, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in Mauritius has been experiencing a steady growth over the past few years.

Customer preferences: Mauritius has a high prevalence of cancer, with breast, lung, and colorectal cancers being the most common types. As a result, there is a high demand for oncology drugs in the country. Patients in Mauritius prefer drugs that are effective, affordable, and have minimal side effects.

Trends in the market: The oncology drugs market in Mauritius is expected to continue growing due to the increasing prevalence of cancer in the country. There has been a shift towards targeted therapies and immunotherapies, which offer better outcomes and fewer side effects compared to traditional chemotherapy. The government has also been implementing initiatives to improve cancer care and treatment in the country, which is expected to drive the growth of the oncology drugs market.

Local special circumstances: Mauritius has a small population, which limits the market size for oncology drugs. However, the country has a well-developed healthcare system and a high standard of living, which makes it an attractive market for pharmaceutical companies. The government has also been implementing policies to promote the use of generic drugs, which has led to increased competition and lower prices for oncology drugs.

Underlying macroeconomic factors: Mauritius has a stable economy with a growing middle class, which has increased the affordability of healthcare and pharmaceuticals. The government has also been investing in healthcare infrastructure and services, which has improved access to cancer care and treatment. However, the country still faces challenges such as a shortage of healthcare professionals and limited resources for cancer prevention and screening.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.